Patent · US Active

Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism

US12037362B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

GENETHON · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
UNIVERSITE D'EVRY VAL D'ESSONNE · FR
Sorbonne Universite · FR
ASSOCIATION INSTITUT DE MYOLOGIE · FR

Inventors

Isabelle Richard · Évreux, FR
Evelyne Gicquel · Vert-le-Petit, FR
Federico Mingozzi · Paris, FR

Key dates

Filing date	Apr 4, 2019
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Apr 11, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14171
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins, wherein said recombinant hybrid AAV capsid protein has a reduced liver tropism compared to the parent AAV9 and AAVrh74 capsid proteins. The invention relates also to the derived hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.